Long-term Disease Course of Crohn’s Disease: Changes in Disease Location, Phenotype, Activities, and Predictive Factors

다국어 초록 (Multilingual Abstract)

Crohn’s disease (CD) is a chronic destructive inflammatory bowel disease that affects young people and is associated with significant morbidity. The clinical spectrum and disease course of CD are heterogeneous and often difficult to predict based on the initial presentation. In this article, changes in the disease location, behavior, clinical course during long-term follow-up, and predictive factors are reviewed. Generally, four different patterns of clinical course are discussed: remission, stable disease, chronic relapsing disease, and chronic refractory disease. Understanding the long-term disease course of CD is mandatory to reveal the underlying pathophysiology of the disease and to move toward a more optimistic disease course, such as remission or stability, and less adverse outcomes or devastating sequelae.

참고문헌 (Reference)

1 Hoffmann P, "Ustekinumab : "Realworld"outcomes and potential predictors of nonresponse in treatment-refractory Crohn’s disease" 25 : 4481-4492, 2019

2 Riordan AM, "Treatment of active Crohn’s disease by exclusion diet : East Anglian multicentre controlled trial" 342 : 1131-1134, 1993

3 Cheifetz AS, "The risk of retention of the capsule endoscope in patients with known or suspected Crohn’s disease" 101 : 2218-2222, 2006

4 Allez M, "The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn’s disease after failure of two other anti-TNF antibodies" 31 : 92-101, 2010

5 Alric H, "The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn’s disease refractory to anti-tumour necrosis factor" 51 : 948-957, 2020

6 Cuthbert AP, "The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease" 122 : 867-874, 2002

7 Kalaria R, "Temporal change in phenotypic behaviour in patients with Crohn’s disease : do Indian patients behave differently from Western and other Asian patients" 10 : 255-261, 2016

8 Makharia GK, "Survey of inflammatory bowel diseases in India" 31 : 299-306, 2012

9 Tibble JA, "Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease" 119 : 15-22, 2000

10 Oberhuber G, "Significant association of strictures and internal fistula formation in Crohn’s disease" 437 : 293-297, 2000

11 Peyrin-Biroulet L, "Selecting Therapeutic Targets in Inflammatory Bowel Disease(STRIDE) : determining therapeutic goals for treat-to-target" 110 : 1324-1338, 2015

12 Turner D, "STRIDE-II : an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease(STRIDE)initiative of the International Organization for the Study of IBD(IOIBD) : determining therapeutic goals for treat-to-target strategies in IBD" 160 : 1570-1583, 2021

13 Benitez JM, "Role of endoscopy, cross-sectional imaging and biomarkers in Crohn’s disease monitoring" 62 : 1806-1816, 2013

14 Thia KT, "Risk factors associated with progression to intestinal complications of Crohn’s disease in a population-based cohort" 139 : 1147-1155, 2010

15 Ben-Horin S, "Review article : loss of response to anti-TNF treatments in Crohn’s disease" 33 : 987-995, 2011

16 Jones J, "Relationships between disease activity and serum and fecal biomarkers in patients with Crohn’s disease" 6 : 1218-1224, 2008

17 Colombel JF, "Randomised clinical trial : deep remission in biologic and immunomodulator naïve patients with Crohn’s disease. A SONIC post hoc analysis" 41 : 734-746, 2015

18 Binder V, "Prognosis in Crohn’s disease : based on results from a regional patient group from the county of Copenhagen" 26 : 146-150, 1985

19 Dalal RS, "Predictors of ustekinumab failure in Crohn’s disease after dose intensification" 27 : 1294-1301, 2021

20 Loly C, "Predictors of severe Crohn’s disease" 43 : 948-954, 2008

21 D’Arcangelo G, "Predictors of longterm clinical and endoscopic remission in children with Crohn disease treated with infliximab" 68 : 841-846, 2019

22 Kennedy NA, "Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn’s disease : a prospective, multicentre, cohort study" 4 : 341-353, 2019

23 Beaugerie L, "Predictors of Crohn’s disease" 130 : 650-656, 2006

24 Laharie D, "Prediction of Crohn’s disease relapse with faecal calprotectin in infliximab responders : a prospective study" 34 : 462-469, 2011

25 Siegel CA, "Predicting response to anti-TNF agents for the treatment of Crohn’s disease" 2 : 245-251, 2009

26 Bitton A, "Predicting relapse in Crohn’s disease : a biopsychosocial model" 57 : 1386-1392, 2008

27 Cucchiara S, "Polymorphisms of tumor necrosis factor-alpha but not MDR1 influence response to medical therapy in pediatric-onset inflammatory bowel disease" 44 : 171-179, 2007

28 Lakatos PL, "Perianal disease, small bowel disease, smoking, prior steroid or early azathioprine/biological therapy are predictors of disease behavior change in patients with Crohn’s disease" 15 : 3504-3510, 2009

29 Tarrant KM, "Perianal disease predicts changes in Crohn’s disease phenotyperesults of a population-based study of inflammatory bowel disease phenotype" 103 : 3082-3093, 2008

30 Nguyen GC, "Outcomes of patients with Crohn’s disease improved from 1988 to 2008and were associated with increased specialist care" 141 : 90-97, 2011

31 Timmer A, "Oral contraceptive use and smoking are risk factors for relapse in Crohn’s disease. The Canadian Mesalamine for Remission of Crohn’s Disease Study Group" 114 : 1143-1150, 1998

32 Ben-Horin S, "Optimizing anti-TNF treatments in inflammatory bowel disease" 13 : 24-30, 2014

33 Schnitzler F, "Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn’s disease" 15 : 1295-1301, 2009

34 Lichtenstein GR, "Management of Crohn’s disease in adults" 104 : 465-483, 2009

35 Hanauer SB, "Maintenance infliximab for Crohn’s disease : the ACCENT I randomised trial" 359 : 1541-1549, 2002

36 Ben-Horin S, "Loss of response to anti-tumor necrosis factors : what is the next step" 32 : 384-388, 2014

37 Gisbert JP, "Loss of response and requirement of infliximab dose intensification in Crohn’s disease : a review" 104 : 760-767, 2009

38 Schnitzler F, "Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease : results from a single-centre cohort" 58 : 492-500, 2009

39 Cosnes J, "Long-term evolution of disease behavior of Crohn’s disease" 8 : 244-250, 2002

40 Amre DK, "Investigating the hygiene hypothesis as a risk factor in pediatric onset Crohn’s disease : a case-control study" 101 : 1005-1011, 2006

41 Colombel JF, "Infliximab, azathioprine, or combination therapy for Crohn’s disease" 362 : 1383-1395, 2010

42 Lémann M, "Infliximab plus azathioprine for steroid-dependent Crohn’s disease patients : a randomized placebo-controlled trial" 130 : 1054-1061, 2006

43 Golovics PA, "Inflammatory bowel disease course in Crohn’s disease : is the natural history changing" 20 : 3198-3207, 2014

44 Bendtzen K, "Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab" 54 : 3782-3789, 2006

45 Ng SC, "Incidence and phenotype of inflammatory bowel disease based on results from the Asia-Pacific Crohn’s and Colitis Epidemiology Study" 145 : 158-165, 2013

46 Jeuring SF, "Improvements in the long-term outcome of Crohn’s disease over the past two decades and the relation to changes in medical management : results from the population-based IBDSL cohort" 112 : 325-336, 2017

47 Peyrin-Biroulet L, "Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn’s disease" 60 : 930-936, 2011

48 Sahmoud T, "Identifying patients with a high risk of relapse in quiescent Crohn’s disease. The GETAID Group. The Groupe d’Etudes Thérapeutiques des Affections Inflammatoires Digestives" 37 : 811-818, 1995

49 Liverani E, "How to predict clinical relapse in inflammatory bowel disease patients" 22 : 1017-1033, 2016

50 Bernstein CN, "Hospitalisations and surgery in Crohn’s disease" 61 : 622-629, 2012

51 Wisniewski A, "Evolving treatment algorithms in Crohn’s disease" 19 : 782-790, 2018

52 Stange EF, "European evidence based consensus on the diagnosis and management of Crohn’s disease : definitions and diagnosis" 55 (55): i1-i15, 2006

53 Doherty G, "European Crohn’s and Colitis Organisation topical review on treatment withdrawal [‘Exit Strategies’] in inflammatory bowel disease" 12 : 17-31, 2018

54 Aniwan S, "Epidemiology, natural history, and risk stratification of Crohn’s disease" 46 : 463-480, 2017

55 Cosnes J, "Epidemiology and natural history of inflammatory bowel diseases" 140 : 1785-1794, 2011

56 Sands BE, "Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed" 147 : 618-627, 2014

57 Sutherland LR, "Effect of cigarette smoking on recurrence of Crohn’s disease" 98 (98): 1123-1128, 1990

58 D’Haens G, "Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease : an open randomised trial" 371 : 660-667, 2008

59 Sandborn WJ, "Dosage adjustment during long-term adalimumab treatment for Crohn’s disease : clinical efficacy and pharmacoeconomics" 17 : 141-151, 2011

60 García-Sánchez V, "Does fecal calprotectin predict relapse in patients with Crohn’s disease and ulcerative colitis" 4 : 144-152, 2010

61 Wintjens D, "Disease activity patterns of Crohn’s disease in the first ten years after diagnosis in the population-based IBD South Limburg cohort" 15 : 391-400, 2021

62 Munkholm P, "Disease activity courses in a regional cohort of Crohn’s disease patients" 30 : 699-706, 1995

63 Pariente B, "Development of the Crohn’s disease digestive damage score, the Lémann score" 17 : 1415-1422, 2011

64 Carbonnel F, "Crohn’s disease severity in familial and sporadic cases" 44 : 91-95, 1999

65 Alvarez-Lobos M, "Crohn’s disease patients carrying Nod2/CARD15 gene variants have an increased and early need for first surgery due to stricturing disease and higher rate of surgical recurrence" 242 : 693-700, 2005

66 Das K, "Crohn’s disease in India : a multicenter study from a country where tuberculosis is endemic" 54 : 1099-1107, 2009

67 Jones VA, "Crohn’s disease : maintenance of remission by diet" 2 : 177-180, 1985

68 Bayless TM, "Crohn’s disease : concordance for site and clinical type in affected family members. Potential hereditary influences" 111 : 573-579, 1996

69 Beaugerie L, "Clinical, serological and genetic predictors of inflammatory bowel disease course" 18 : 3806-3813, 2012

70 Kenji Watanabe, "Clinical management for small bowel of Crohn’s disease in the treat-to-target era: now is the time to optimize treatment based on the dominant lesion" 대한장연구학회 18 (18): 347-354, 2020

71 Ye BD, "Clinical features and longterm prognosis of Crohn’s disease in Korea" 45 : 1178-1185, 2010

72 Rönnblom A, "Clinical course of Crohn’s disease in a population-based cohort in Uppsala County followed for 10 years" 55 : 1301-1307, 2020

73 Latella G, "Clinical course of Crohn’s disease first diagnosed at surgery for acute abdomen" 41 : 269-276, 2009

74 Henriksen M, "Clinical course in Crohn’s disease : results of a five-year population-based follow-up study(the IBSEN study)" 42 : 602-610, 2007

75 Solberg IC, "Clinical course in Crohn’s disease : results of a Norwegian population-based ten-year follow-up study" 5 : 1430-1438, 2007

76 Silverstein MD, "Clinical course and costs of care for Crohn’s disease : Markov model analysis of a population-based cohort" 117 : 49-57, 1999

77 Hansel SL, "Clinical benefit of capsule endoscopy in Crohn’s disease : impact on patient management and prevalence of proximal small bowel involvement" 24 : 1582-1588, 2018

78 김덕환 ; 김원호 ; 천재희 ; 박재준 ; 윤진영 ; 문창모 ; 홍성필 ; 김태일, "Clinical Outcomes and Predictive Factors for Response after the First Course of Corticosteroid Therapy in Patients with Crohn’s Disease" 거트앤리버 소화기연관학회협의회 7 (7): 58-65, 2013

79 Rungoe C, "Changes in medical treatment and surgery rates in inflammatory bowel disease : a nationwide cohort study 1979-2011" 63 : 1607-1616, 2014

80 Lo B, "Changes in disease behaviour and location in patients with Crohn’s disease after seven years of follow-up : a Danish population-based inception cohort" 12 : 265-272, 2018

81 Jess T, "Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades : a population-based study from Copenhagen, Denmark" 13 : 481-489, 2007

82 Chow DK, "Changes in Crohn's disease phenotype over time in the Chinese population : validation of the Montreal classification system" 14 : 536-541, 2008

83 Vegh Z, "Can we predict disease course with clinical factors" 19 : 791-797, 2018

84 D’Incà R, "Can calprotectin predict relapse risk in inflammatory bowel disease" 103 : 2007-2014, 2008

85 Newman B, "CARD15 and HLA DRB1 alleles influence susceptibility and disease localization in Crohn’s disease" 99 : 306-315, 2004

86 Louis E, "Behaviour of Crohn’s disease according to the Vienna classification : changing pattern over the course of the disease" 49 : 777-782, 2001

87 Henriksen M, "Are there any differences in phenotype or disease course between familial and sporadic cases of inflammatory bowel disease? Results of a population-based follow-up study" 102 : 1955-1963, 2007

88 Lichtenstein GR, "Approach to corticosteroid-dependent and corticosteroid-refractory Crohn’s disease" 7 (7): S23-S29, 2001

89 Roblin X, "Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies : a prospective randomised trial" 69 : 1206-1212, 2020

90 Colombel JF, "Adalimumab induces deep remission in patients with Crohn’s disease" 12 : 414-422, 2014

91 Rutgeerts P, "Adalimumab induces and maintains mucosal healing in patients with Crohn’s disease : data from the EXTEND trial" 142 : 1102-1111, 2012

92 Targan SR, "A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2Study Group" 337 : 1029-1035, 1997

93 Feagan B, "A randomized trial of methotrexate in combination with infliximab for the treatment of Crohn’s disease" 135 : 294-295, 2008

94 Naismith GD, "A prospective evaluation of the predictive value of faecal calprotectin in quiescent Crohn’s disease" 8 : 1022-1029, 2014

95 Oussalah A, "A multicenter experience with infliximab for ulcerative colitis : outcomes and predictors of response, optimization, colectomy, and hospitalization" 105 : 2617-2625, 2010

96 Gajendran M, "A comprehensive review and update on Crohn’s disease" 64 : 20-57, 2018

97 Gomollón F, "3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016 : part 1. Diagnosis and medical management" 11 : 3-25, 2017